Simris Alg AB Class B (SE:SIMRIS.B)
:SIMRIS.B
Top Page
Simris Alg AB Class B
(SIMRIS.B)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr0.08
▲(95.00% Upside)
Action:UpgradedDate:03/02/26
The score is weighed down primarily by very weak financial performance (shrinking revenue, heavy losses, ongoing cash burn, and deteriorating balance sheet with negative equity and higher debt). Technicals are mixed and only mildly supportive, while valuation offers limited comfort due to negative earnings and no dividend yield.
Positive Factors
Vertical integration in production
Owning cultivation through commercialization gives durable control of feedstock, quality and yields. Vertical integration can protect margins, reduce supplier risk and enable product consistency over time, supporting scalable production if demand and execution improve.
Negative Factors
Shrinking revenue
Sustained steep revenue declines erode scale benefits and weaken the go‑to‑market thesis. Falling top line undermines the ability to leverage fixed costs, invest in commercialization, and achieve sustainable margins, increasing structural survival risk absent revenue recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Vertical integration in production
Owning cultivation through commercialization gives durable control of feedstock, quality and yields. Vertical integration can protect margins, reduce supplier risk and enable product consistency over time, supporting scalable production if demand and execution improve.
Read all positive factors
Simris Alg AB Class B (SIMRIS.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr109.33M
Dividend YieldN/A
Average Volume (3M)223.88K
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue Growth-49.72%
EPS Growth36.20%
CountrySE
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,349,793,200
10 Day Avg. Volume120,731
30 Day Avg. Volume223,875
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-76.69
Price to Sales (P/S)22.32
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Simris Alg AB Class B Business Overview & Revenue Model
Company Description
Simris Alg AB (publ) manufactures and sells dietary supplements and algae-based foods in Sweden and internationally. It offers Simris Algae Omega-3, a plant-based marine omega-3 EPA and DHA line; and a line of algae-based products, such as finest ...
How the Company Makes Money
null...
Simris Alg AB Class B Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
6
Very Negative
Cash Flow
8
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.61M | 2.89M | 4.35M | 4.08M | 6.14M |
| Gross Profit | -31.34M | 1.22M | 2.01M | -742.00K | -2.07M |
| EBITDA | -17.32M | -17.59M | -22.36M | -18.00M | -24.81M |
| Net Income | -26.81M | -34.60M | -37.30M | -24.42M | -28.36M |
Balance Sheet | |||||
| Total Assets | 148.38M | 157.06M | 174.55M | 185.71M | 29.20M |
| Cash, Cash Equivalents and Short-Term Investments | 1.47M | 1.95M | 5.67M | 3.99M | 961.00K |
| Total Debt | 87.68M | 2.04M | 2.67M | 2.13M | 3.13M |
| Total Liabilities | 148.85M | 151.42M | 148.94M | 162.68M | 10.98M |
| Stockholders Equity | -470.00K | 5.64M | 25.61M | 23.03M | 18.22M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -18.63M | -37.96M | -40.57M | -18.39M |
| Operating Cash Flow | -16.05M | -18.02M | -36.35M | -18.19M | -18.14M |
| Investing Cash Flow | -224.00K | -613.00K | -1.61M | -22.38M | -253.00K |
| Financing Cash Flow | 15.79M | 14.91M | 39.63M | 43.60M | 2.84M |
Simris Alg AB Class B Technical Analysis
Negative
0.04
Price Trends
0.10
Negative
0.09
Negative
0.12
Negative
Market Momentum
>-0.01
Positive
43.17
Neutral
31.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SIMRIS.B, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.12, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.17 is Neutral, neither overbought nor oversold. The STOCH value of 31.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SIMRIS.B.
Simris Alg AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr95.25M | ― | -601.02% | ― | ― | ― | |
47 Neutral | kr80.07M | -5.14 | -202.18% | ― | ― | 20.55% | |
43 Neutral | kr109.33M | -1.34 | ― | ― | -49.72% | 36.20% | |
43 Neutral | kr36.61M | -1.03 | -457.91% | ― | ― | -19.35% | |
41 Neutral | kr3.64M | -3.06 | -213.85% | ― | ― | ― | |
40 Underperform | kr24.68M | -1.19 | -88.65% | ― | 8.46% | 11.73% |
* Healthcare Sector Average
SE:SIMRIS.B
Simris Alg AB Class B
0.08
-0.02
-21.36%
SE:PILA
PILA PHARMA AB
2.09
-0.59
-21.94%
SE:ONCOZ
OncoZenge AB
5.70
1.40
32.40%
SE:LPGO
Lipigon Pharmaceuticals AB
0.01
-0.08
-87.78%
SE:MODTX
Modus Therapeutics Holding AB
0.30
-0.15
-33.85%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
6.99
-11.45
-62.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.